ES2660339T3 - Derivados de galato de (-)-epigalocatequina para inhibir el proteasoma - Google Patents

Derivados de galato de (-)-epigalocatequina para inhibir el proteasoma Download PDF

Info

Publication number
ES2660339T3
ES2660339T3 ES05779886.0T ES05779886T ES2660339T3 ES 2660339 T3 ES2660339 T3 ES 2660339T3 ES 05779886 T ES05779886 T ES 05779886T ES 2660339 T3 ES2660339 T3 ES 2660339T3
Authority
ES
Spain
Prior art keywords
cells
egcg
group
compound
proteasome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05779886.0T
Other languages
English (en)
Spanish (es)
Inventor
Tak-Hang Chan
Wai-Har Lam
Larry Ming-Cheung Chow
Qing Ping DOU
Deborah Joyce Kuhn
Aslamuzzaman KAZI
Sheng Biao Wan
Kristin R. Landis-Piwowar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Hong Kong Polytechnic University HKPU
Wayne State University
University of South Florida
University of South Florida St Petersburg
Original Assignee
McGill University
Hong Kong Polytechnic University HKPU
Wayne State University
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/921,332 external-priority patent/US7544816B2/en
Application filed by McGill University, Hong Kong Polytechnic University HKPU, Wayne State University, University of South Florida, University of South Florida St Petersburg filed Critical McGill University
Application granted granted Critical
Publication of ES2660339T3 publication Critical patent/ES2660339T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
ES05779886.0T 2004-08-19 2005-08-15 Derivados de galato de (-)-epigalocatequina para inhibir el proteasoma Expired - Lifetime ES2660339T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/921,332 US7544816B2 (en) 2004-08-19 2004-08-19 (−)-Epigallocatechin gallate derivatives for inhibiting proteasome
US921332 2004-08-19
US64956905P 2005-02-04 2005-02-04
US649569P 2005-02-04
PCT/CN2005/001262 WO2006017981A1 (en) 2004-08-19 2005-08-15 (-)-epigallocatechin gallate derivatives for inhibiting proteasome

Publications (1)

Publication Number Publication Date
ES2660339T3 true ES2660339T3 (es) 2018-03-21

Family

ID=35907224

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05779886.0T Expired - Lifetime ES2660339T3 (es) 2004-08-19 2005-08-15 Derivados de galato de (-)-epigalocatequina para inhibir el proteasoma

Country Status (6)

Country Link
US (4) US8193377B2 (https=)
EP (1) EP1778663B1 (https=)
JP (1) JP5265915B2 (https=)
CN (1) CN101072764B (https=)
ES (1) ES2660339T3 (https=)
WO (1) WO2006017981A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778663B1 (en) 2004-08-19 2017-12-13 The Hong Kong Polytechnic University (-)-epigallocatechin gallate derivatives for inhibiting proteasome
EP2088205A1 (en) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: A diagnosis marker and therapeutic target of chronic rejection.
US8784873B2 (en) * 2009-07-22 2014-07-22 Naturewise Biotech & Medicals Corporation Use of histone deacetylase inhibitors in changing MRJP3 protein in royal jelly
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
GB2500136B (en) 2010-10-15 2015-02-18 Microsoft Corp Parasitic folded loop antenna
CN102078316A (zh) * 2011-01-24 2011-06-01 广西医科大学 表没食子儿茶素没食子酸酯衍生物在抗肿瘤药物中的应用
CN102153535A (zh) * 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
EP2557079A1 (en) * 2011-08-09 2013-02-13 Nestec S.A. Synthesis of catechin and epicatechin conjugates
WO2017132775A1 (en) * 2016-02-05 2017-08-10 Viteava Pharmaceuticals Inc. Novel compositions and methods for the treatment of leiomyoma
CN108129438A (zh) * 2017-12-25 2018-06-08 中国海洋大学 一种含2-苯色满母核的化合物及其制备方法
KR102057773B1 (ko) 2018-03-30 2019-12-19 건국대학교 산학협력단 에피갈로카테킨 갈레이트 유도체를 포함하는 유방암 예방 또는 치료용 약학적 조성물
JP2021527048A (ja) * 2018-06-05 2021-10-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 癌治療のためのアシル化カテキンポリフェノールおよびその使用方法
CN116162078B (zh) * 2022-12-27 2024-10-29 佛山病原微生物研究院 一种表没食子儿茶素没食子酸酯类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57118580A (en) * 1981-01-16 1982-07-23 Kanebo Ltd Novel catechin derivative
JPS57120584A (en) * 1981-01-20 1982-07-27 Kanebo Ltd Production of catechin derivative
JPH10254087A (ja) * 1997-03-14 1998-09-25 Konica Corp ハロゲン化銀写真感光材料
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
US7122573B2 (en) * 2002-12-06 2006-10-17 Sri International Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents
US7544816B2 (en) * 2004-08-19 2009-06-09 The Hong Kong Polytechnic University (−)-Epigallocatechin gallate derivatives for inhibiting proteasome
EP1778663B1 (en) * 2004-08-19 2017-12-13 The Hong Kong Polytechnic University (-)-epigallocatechin gallate derivatives for inhibiting proteasome

Also Published As

Publication number Publication date
US9169230B2 (en) 2015-10-27
JP5265915B2 (ja) 2013-08-14
JP2008509939A (ja) 2008-04-03
US8193377B2 (en) 2012-06-05
CN101072764A (zh) 2007-11-14
US20080176931A1 (en) 2008-07-24
WO2006017981A9 (en) 2006-05-11
WO2006017981A1 (en) 2006-02-23
CN101072764B (zh) 2013-07-10
EP1778663A4 (en) 2008-08-06
US20160068503A1 (en) 2016-03-10
US20140213802A1 (en) 2014-07-31
EP1778663A1 (en) 2007-05-02
US8710248B2 (en) 2014-04-29
US20120232135A1 (en) 2012-09-13
EP1778663B1 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
US9169230B2 (en) (−)-Epigallocatechin gallate derivatives for inhibiting proteasome
US20070099826A1 (en) Treatment of diseases associated with the egr-1 enhancer element
Li et al. Potent hydrazone derivatives targeting esophageal cancer cells
Jia et al. The synthesis and biological evaluation of novel Danshensu–cysteine analog conjugates as cardiovascular-protective agents
Mahfouz et al. Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/isatin esters of some NSAIDs as prodrugs with an improved therapeutic index
EP3137554A1 (en) Azoaryls as reversibly modulatable tubulin inhibitors
Wan et al. Evaluation of curcumin acetates and amino acid conjugates as proteasome inhibitors
Kwak et al. Blood-brain barrier-permeable fluorone-labeled dieckols acting as neuronal ER stress signaling inhibitors
US7544816B2 (en) (−)-Epigallocatechin gallate derivatives for inhibiting proteasome
Huo et al. Proteasome inhibition in human breast cancer cells with high catechol-O-methyltransferase activity by green tea polyphenol EGCG analogs
Hiza et al. Synthetic studies of fisetin, myricetin and nobiletin analogs and related probe molecules
Pang et al. The synthesis and evaluation of new butadiene derivatives as tubulin polymerization inhibitors
SK50062012A3 (sk) Quercetin derivatives, pharmaceutical compositions comprising them and their use
Feng et al. The novel synthetic triterpene methyl 3β-O-[4-(2-Aminoethylamino)-4-oxo-butyryl] olean-12-ene-28-oate inhibits breast tumor cell growth in vitro and in vivo
CN108658915A (zh) 一类含有香豆素结构的异羟肟酸类化合物、用途及其制备方法
Osanai et al. Synthesis of (2R, 3R)-epigallocatechin-3-O-(4-hydroxybenzoate), a novel catechin from Cistus salvifolius, and evaluation of its proteasome inhibitory activities
Das et al. Design, synthesis of novel peptidomimetic derivatives of 4-HPR for rhabdoid tumors
Chan et al. inhibiting proteasome
Odens et al. Inhibition of the thioesterase activity of human fatty acid synthase by 1, 4-and 9, 10-diones
WO2002012167A1 (es) Derivados de acido araquidonico con afinidad por el transportador de anandamida
Bhattarai Ramalin, a Novel Phenyl Hydrazide from the Lichen Ramalina Terebrata; Isolation, Total Synthesis and Biological Activities
WO2019129909A1 (es) Benzopiranos prenilados agonistas de ppar
Huo et al. Structural modification and biological evaluation of spirolactone type ent-kauranoid isodonal as potential anti-melanoma agents
US10519179B2 (en) Highly efficient NRF2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
JP2018070509A (ja) 新規トコフェリルアスコルビン酸誘導体とその製造方法